Progress in medicinal chemistry最新文献_第9页

Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. 数字药物化学:现代药物设计的物理化学、热力学和动力学。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/s0079-6468(09)04801-2

Graham F Smith

引用次数: 33

Progress in the development of beta-secretase inhibitors for Alzheimer's disease. 阿尔茨海默病β -分泌酶抑制剂的研究进展。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/s0079-6468(09)04804-8

Jeffrey S Albert

{"title":"Progress in the development of beta-secretase inhibitors for Alzheimer's disease.","authors":"Jeffrey S Albert","doi":"10.1016/s0079-6468(09)04804-8","DOIUrl":"https://doi.org/10.1016/s0079-6468(09)04804-8","url":null,"abstract":"<p><p>Since the original identification of BACE in 1999 and until quite recently, BACE was often regarded as a \"difficult\" drug target, much as renin has proven to be. The reasons for this include the following. First, the long and shallow nature of the substrate binding pocket suggested that it would not be possible to identify small molecule drugs that could have adequate binding affinity. Second, functional groups that typically interact with the active site aspartates are usually highly polarized and, therefore, contribute to reduced CNS localization. Early BACE inhibitors were all designed using knowledge of the peptide substrates and usually contained some variation of a few well-known transition-state isosteres. While these had great impact on fundamental understanding of the enzyme structure and key interaction regions, they were very large, very polar, and had essentially no CNS availability. Continued progress by reducing the peptidic nature of these compounds resulted in incremental advances and has provided compounds that meet, or nearly meet, typical CNS drug-like criteria. The challenges associated with peptidic starting points inspired innovative new approaches to search for different starting points. Several groups employed high concentration screening (ligand concentration 100 microM and higher) to find weak hits after conventional screening (typically at 10 microM) failed to find more potent ones. Fragment-based methods have also been developed to identify even weaker hits (IC50 1 mM and greater). This was accomplished through the evolution and refinement of several detection methodologies including calorimetry, surface plasmon resonance, NMR, and crystallography. Coupled with detailed structural understanding of ligand-enzyme interactions and focus on maintaining ligand efficiency, these developments have resulted in several examples where potency was improved by 10,000-fold to afford compounds with IC50 values < 10 nM and promising drug-like characteristics. Together, all these efforts have afforded a diverse array of chemotypes as BACE inhibitors. Early work focused on improving BACE potency in isolated enzyme assays. However, most of these compounds showed potency reductions in cellular assays. Continued improvements in drug properties and in understanding of the physiologically relevant conditions have resulted in many compounds that show strong potency in both isolated and cellular assays. Several compounds have shown reduction of Abeta using rodent in-vivo models both peripherally and in the brain. Recently, one compound has demonstrated reduction of brain Abeta levels in a non-human primate. Phase I clinical trials were initiated on BACE inhibitor CTS-21166 from CoMentis in July of 2007. This compound derives from the earliest described peptidic inhibitors such as OM99-2 [58] but no details have been reported. In addition to strategies involving small molecule inhibitors of BACE and gamma-secretase to reduce Abeta levels","PeriodicalId":20755,"journal":{"name":"Progress in medicinal chemistry","volume":"48 ","pages":"133-61"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0079-6468(09)04804-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30163920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35

Progress in medicinal chemistry. Preface. 药物化学进展。前言。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/S0079-6468(08)00208-7

G Lawton, D R Witty

引用次数: 1

Advances in the design of 5-HT6 receptor ligands with therapeutic potential. 具有治疗潜力的5-HT6受体配体的设计进展。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/s0079-6468(09)04805-x

David Witty, Mahmood Ahmed, Tsu Tshen Chuang

引用次数: 22

The adenosine A1 receptor and its ligands. 腺苷A1受体及其配体。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/S0079-6468(08)00204-X

Peter G Nell, Barbara Albrecht-Küpper

引用次数: 24

Beginning of the 'numbers' era of medicinal chemistry. Preface. 药物化学的“数字”时代开始了。前言。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/S0079-6468(09)04810-3

G Lawton, D R Witty

引用次数: 0

Calcitonin gene-related peptide receptor antagonists for the treatment of migraine. 降钙素基因相关肽受体拮抗剂治疗偏头痛。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/S0079-6468(08)00201-4

Theresa M Williams, Christopher S Burgey, Christopher A Salvatore

引用次数: 2

Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. 用于治疗慢性疾病的磷酸肌苷3-激酶(PI3K)抑制剂的设计和开发进展。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/s0079-6468(09)04803-6

Stephen Shuttleworth, Franck Silva, Cyrille Tomassi, Alexander Cecil, Thomas Hill, Helen Rogers, Paul Townsend

引用次数: 11

The identification of and rationale for drugs which act at the motilin receptor. 对运动素受体起作用的药物的鉴定和原理。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/s0079-6468(09)04802-4

Susan M Westaway, Gareth J Sanger

引用次数: 18

PDE4 inhibitors - a review of the current field. PDE4抑制剂-当前领域综述。

Progress in medicinal chemistry Pub Date : 2009-01-01 DOI: 10.1016/S0079-6468(08)00202-6

Neil J Press, Katharine H Banner

引用次数: 58